34385PAA6

Standard Biotools Inc.

Could not find a ticker for this position, may be a filing error

A maker of scientific instruments used by biomedical researchers to study individual cells and proteins. Its three platforms—CyTOF mass cytometry, Hyperion spatial proteomics, and Biomark genomics—are sold to academic labs, translational centers, and biopharma companies. Founded in 1999 as Mycometrix and renamed Fluidigm in 2001 (a play on the "fluid" microchips it builds), the company became Standard BioTools in 2022, after its microfluidics "integrated fluidic circuits" were born from a Caltech lab that manipulates fluids on chips much like electronics handle electrons.

NOTEUnderlying: LABCUSIP: 34385PAA6HealthcareUS1 derivative reporter

5.25% Convertible Senior Notes due 2024

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last year

Insider

Casdin Eli +7 co-filersDirector, Director, 10% owner · 18 transactions

105.62M—

Bought 11.82M

Casdin EliDirector, 10% owner · 2 transactions

91.84M+16.3%

Granted 152.1K

Egholm MichaelPresident & CEO, Director · 7 transactions

6.14M+8%

Granted 1.24M

Kim Hanjoon AlexChief Financial Officer · 7 transactions

2.53M+4.4%

Granted 393.4K

Mackay SeanSVP & Chief Business Officer · 6 transactions

1.48M+85.2%

Granted 772.1K

Cox TroyDirector · 2 transactions

475.7K+49%

Granted 156.4K

Carey Thomas D.Director · 2 transactions

344.5K+77.5%

Granted 150.4K

Eloi Fenel MDirector · 1 transaction

335.3K+42%

Granted 99.1K

Witney FrankDirector · 1 transaction

314.2K+46.1%

Granted 99.1K

Hibbs Kathy LDirector · 1 transaction

236.8K+72%

Granted 99.1K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Casdin Eli +7 co-filersDirector, Director, 10% owner · 18 transactions	—	105.62M	—	11.82M	—
Casdin EliDirector, 10% owner · 2 transactions	+16.3%	91.84M	152.1K	—	—
Egholm MichaelPresident & CEO, Director · 7 transactions	+8%	6.14M	1.24M	—	—
Kim Hanjoon AlexChief Financial Officer · 7 transactions	+4.4%	2.53M	393.4K	—	—
Mackay SeanSVP & Chief Business Officer · 6 transactions	+85.2%	1.48M	772.1K	—	—
Cox TroyDirector · 2 transactions	+49%	475.7K	156.4K	—	—
Carey Thomas D.Director · 2 transactions	+77.5%	344.5K	150.4K	—	—
Eloi Fenel MDirector · 1 transaction	+42%	335.3K	99.1K	—	—
Witney FrankDirector · 1 transaction	+46.1%	314.2K	99.1K	—	—
Hibbs Kathy LDirector · 1 transaction	+72%	236.8K	99.1K	—	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.